세계의 톡소이드 백신 시장(2023-2030년)

Market Overview

The global toxoid vaccine market reached US$ 5,585.6 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 8,267.2 million by 2030. The market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The presence of key market players holding the majority of the toxoid vaccine market share in the Asia-Pacific region ensures the growth of this region at a high CAGR rate.

For instance, in October 2022, Panacea Biotec, one of India's leading biotechnology companies, received long-term supply awards worth US$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for the supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).

Moreover, in September 2022, after a successful run with its covid vaccine, the Serum Institute of India focused on designing a vaccine for Diphtheria, Pertussis, and Tetanus (Tdap). The company has presented its phase 2-3 clinical trial data to the Drugs Control General of India (DCGI)'s expert panel seeking permission to manufacture the vaccines. Thus, the data indicate that the Asia-Pacific toxoid market will grow at a high CAGR throughout the forecast period.

The global toxoid vaccine market is the market for vaccines that use toxoids as antigens to create an immune response against specific bacterial diseases, such as tetanus. This type of vaccine is particularly effective at providing protection against tetanus in adults and children aged seven years or older.

The market for toxoid vaccines is expected to grow at a significant rate due to several factors, including the rising prevalence of infectious diseases, increased awareness of the benefits of vaccination, and government-led initiatives aimed at promoting vaccination programs. In addition, ongoing research and development activities and new product launches by major players in the market are expected to further boost the growth of the global toxoid vaccine market.

Market Dynamics

The rising number of government-funded programs to prevent infectious diseases is expected to drive the growth of the global toxoid vaccine market

Government initiatives for toxoid vaccine, such as the Maternal and Neonatal Tetanus Elimination (MNTE) initiative, play a crucial role in driving the global toxoid vaccine market growth. Maternal and Neonatal Tetanus (MNT) is a life-threatening disease that can occur due to unclean deliveries and umbilical cord care practices. The MNTE initiative aims to reduce the number of MNT cases to such low levels that the disease is no longer a major public health problem.

Governments and international organizations, such as the World Health Organization (WHO), have been actively supporting the MNTE initiative by providing funding for immunization programs and public health campaigns. As a result of these initiatives, the global toxoid vaccine market is expected to grow significantly over the forecast period.

The global toxoid vaccine market growth may face constraints due to allergic reactions caused by these vaccines.

The use of the tetanus toxoid vaccine is limited by the occurrence of local reactions such as pain and redness at the site of injection, as well as systemic reactions like fever, fatigue, and muscle pain. Although severe allergic reactions to the vaccine are rare, they can be a concern for a small percentage of people.

Moreover, the incidence of tetanus has declined significantly due to widespread vaccination, resulting in a reduction in demand for the vaccine. The market for tetanus toxoid vaccine is characterized by a dichotomy between the contractual market, which holds a significant share, and the private market.

COVID-19 Impact Analysis

The toxoid vaccine market has experienced a somewhat mixed impact from the pandemic. While the demand for tetanus toxoid vaccines has remained stable due to their inclusion in routine immunization schedules, the demand for diphtheria toxoid vaccines has declined because of reduced diphtheria incidence in many areas worldwide.

Despite this, the global toxoid vaccine market is projected to continue growing at a steady pace because of the ongoing necessity for vaccination programs to manage infectious diseases. The pandemic's overall impact on the market is predicted to be moderately significant.

Russia-Ukraine Conflict Analysis

The global toxoid vaccine market has not been significantly affected by the ongoing conflict between Russia and Ukraine, as most of the production and distribution is situated outside the conflict zone. However, there have been reports of disruptions in supply chains and difficulties in accessing medical supplies, including vaccines, due to the conflict in the region.

Furthermore, the conflict has resulted in damage or destruction of healthcare facilities, such as hospitals and clinics, in some areas. This has made it challenging for the country to provide necessary healthcare services, including vaccination programs, to the population.

Segment Analysis

The global toxoid vaccine market is segmented based on disease, composition, end user, and region.

The diphtheria, tetanus, and pertussis (DtaP) segment is expected to hold the highest market share for the global toxoid vaccine market.

The Diphtheria, Tetanus, and Pertussis (DTaP) segment is expected to be the dominant segment in the global toxoid vaccine market, holding 44.2% of the market share over the forecast period. DTaP is a vaccine that helps children under the age of seven develop immunity against three deadly diseases caused by diphtheria, tetanus, and whooping cough (pertussis). The low cost of the vaccine, increasing tetanus cases, and its availability in low-resource economies such as Africa are driving the growth of the DTaP vaccine segment.

In the United States, there are currently seven licensed pediatric DTaP vaccines being used: Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, and Vaxelis. The growth of the DTaP vaccine segment during the forecast period is attributed to the increasing prevalence of diphtheria, tetanus, and pertussis, product launches, rising demand for combination vaccines, and high adoption of DTaP vaccines.

Geographical Analysis

The presence of major players to dominate the North America region.

The toxoid vaccine market is expected to grow significantly in North America region over the forecast period due to the presence of key market players who hold a major global toxoid market share. The market players have implemented various market strategies such as collaborations, disease launches, and acquisitions to expand their reach and increase their toxoid vaccine market share. It is predicted that North America will dominate the global toxoid vaccine market by acquiring around 2/5th of the market share.

For instance, in June 2022, GSK plc, a global pharmaceutical company, invested a significant amount of over US$1.2 billion in R&D to develop vaccines and medicines to prevent and treat various diseases, including malaria, tuberculosis, HIV, neglected tropical diseases, and diphtheria. All these factors indicate that North America is expected to remain the dominant region in the global toxoid vaccine market.

Competitive Landscape

The major global players in the market include Sanofi S.A., Serum Institute of India Pvt. Ltd., Panacea Biotec, Biological E Limited, GlaxoSmithKline, Merck & Co. Inc., Astellas Pharma Inc., Bharat Biotech, Dano Vaccines, and Abbott.

Why Purchase the Report?

• To visualize the global toxoid vaccine- market segmentation based on disease, composition, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global toxoid vaccine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global toxoid vaccine market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease
• 3.2. Snippet by Composition
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The rising number of government-funded programs to prevent infectious diseases is expected to drive the growth of the global toxoid vaccine market
  • 4.1.2. Restraints
    • 4.1.2.1. The global toxoid vaccine market growth may face constraints due to allergic reaction caused by these vaccines
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Before COVID-19 Scenario
  • 6.1.2. Present COVID-19 Scenario
  • 6.1.3. Post COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Disease

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
  • 7.1.2. Market Attractiveness Index, By Disease
• 7.2. Tetanus
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Diphtheria
• 7.4. Pertussis

8. By Composition

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
  • 8.1.2. Market Attractiveness Index, By Composition
• 8.2. Diphtheria, Tetanus, and Pertussis (DtaP)
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Diphtheria and Tetanus (DT)
• 8.4. Tetanus, Diphtheria, and Pertussis (Tdap)
• 8.5. Monovalent Tetanus Toxoid (TT)
• 8.6. Tetanus and Diphtheria (Td)

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals And Clinics
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Government Organizations
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Sanofi S.A.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Serum Institute of India Pvt. Ltd.
• 12.3. Panacea Biotec
• 12.4. Biological E Limited
• 12.5. GlaxoSmithKline
• 12.6. Merck & Co. Inc.
• 12.7. Astellas Pharma Inc.
• 12.8. Bharat Biotech
• 12.9. Dano Vaccines
• 12.10. Abbot

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us